Abstract:Drug addiction, or substance use disorder (SUD), is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behaviour persist despite serious negative consequences. Drug abuse represents a problem that deserves great attention from a social point of view, and focuses on the importance of genetic studies to help in understanding the genetic basis of addiction and its medical treatment. Despite the complexity of drug addiction disorders, and the high number of environmental variables playing a role in the onset, recurrence, and duration of the symptoms, several studies have highlighted the non-negligible role of genetics, as demonstrated by heritability and genome-wide association studies. A correlation between the relative risk of addiction to specific substances and heritability has been recently observed, suggesting that neurobiological mechanisms may be, at least in part, inherited. All these observations point towards a scenario where the core neurobiological factors of addiction, involving the reward system, impulsivity, compulsivity, stress, and anxiety response, are transmitted, and therefore, genes and mutations underlying their variation might be detected. In the last few years, the development of new and more efficient sequencing technologies has paved the way for large-scale studies in searching for genetic and epigenetic factors affecting drug addiction disorders and their treatments. These studies have been crucial to pinpoint single nucleotide polymorphisms (SNPs) in genes that affect the reaction to medical treatments. This is critically important to identify pharmacogenomic approaches for substance use disorder, such as OPRM1 SNPs and methadone required doses for maintenance treatment (MMT). Nevertheless, despite the promising results obtained by genome-wide association and pharmacogenomic studies, specific studies related to population genetics diversity are lacking, undermining the overall applicability of the preliminary findings, and thus potentially affecting the portability and the accuracy of the genetic studies. In this review, focusing on cannabis, cocaine and heroin use, we report the state-of-the-art genomics and pharmacogenomics of SUDs, and the possible future perspectives related to medical treatment response in people that ask for assistance in solving drug-related problems.

Research landscape analysis on dual diagnosis of substance use and mental health disorders: key contributors, research hotspots, and emerging research topics

The epidemiology of dual diagnosis

Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review

Rates and correlates of dual diagnosis among adults with psychiatric and substance use disorders in a nationally representative U.S sample

Co-occurrence of substance use disorders with other psychiatric disorders: Implications for treatment services

Managing the Dual Diagnosis Dilemma of Bipolar Disorder and Substance Abuse in Clinical Settings

Psychosocial Treatments for People with Co-occurring Severe Mental Illnesses and Substance Use Disorders (Dual Diagnosis): A Review of Empirical Evidence

The Evolving Landscape of Substance Use Disorder Mortality in the United States: A Spatiotemporal Analysis of Emerging Hotspots and Vulnerable Populations (2005-2020)

Dual-substance use disorder couples: An integrative review and proposed theoretical model

Mobile Health Interventions for Substance Use Disorders

Craving for a Robust Methodology: A Systematic Review of Machine Learning Algorithms on Substance-Use Disorders Treatment Outcomes

Substance Use Disorders and Medical Comorbidities among High-Need, High-Risk Patients with Diabetes

Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies

Bibliometric Insights in Genetic Factors of Substance-Related Disorders: Intellectual Developments, Turning Points, and Emerging Trends

Substance Use Disorders in Global Mental Health Delivery: Epidemiology, Treatment Gap, and Implementation of Evidence-Based Treatments

Co-occurring mental and substance use disorders in Australia 2020–2022: Prevalence, patterns, conditional probabilities and correlates in the general population

Prevalence, Patterns, and Correlates of Multiple Substance Use Disorders among Adult Primary Care Patients.

Characterizing the Development of Research Landscapes in Substance Use and HIV/AIDS During 1990 to 2021

Residential and inpatient treatment of substance use disorders in Sub-Saharan Africa: a scoping review

Comparing Rates of Undiagnosed Hypertension and Diabetes in Patients With and Without Substance Use Disorders

A scoping review of social determinants of health's impact on substance use disorders over the life course